Exocrine pancreatic insufficiency, which occurs in approximately 20% of the patients with GEP-NENs receiving SSAs octreotide and lanreotide, is an underestimated condition. The clinical picture of EPI in these patients may overlap with tumor-related symptoms and common direct SSAs’ side effects, such as diarrhea, abdominal pain, bloating, and flatulence. Early recognition of EPI is mandatory since it may negatively affect patients’ quality of life, nutritional status, and long-term clinical outcomes.
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia / Panzuto, F.; Magi, L.; Rinzivillo, M.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 20:4(2021), pp. 383-386. [10.1080/14740338.2021.1881478]
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia
Panzuto F.
;Magi L.;Rinzivillo M.
2021
Abstract
Exocrine pancreatic insufficiency, which occurs in approximately 20% of the patients with GEP-NENs receiving SSAs octreotide and lanreotide, is an underestimated condition. The clinical picture of EPI in these patients may overlap with tumor-related symptoms and common direct SSAs’ side effects, such as diarrhea, abdominal pain, bloating, and flatulence. Early recognition of EPI is mandatory since it may negatively affect patients’ quality of life, nutritional status, and long-term clinical outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Panzuto_Exocrine-pancreatic-insufficiency_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
739.43 kB
Formato
Adobe PDF
|
739.43 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
